1.Ibrahim, EH, Sherman, G, Ward, S, et al.The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:146–155.
2.Kollef, MH, Sherman, G, Ward, S, et al.Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462–474.
3.Paterson, DL, Mulazimoglu, L, Casellas, JM, et al.Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000;30:473–478.
4.Kim, Y-K, Pai, H, Lee, H-J, et al.Bloodstream infections by extended-spectrum ß-lactamase producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 2002;46:1481–1491.
5.Kaye, KS, Cosgrove, S, Harris, A, et al.Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother 2001;45:2628–2630.
6.National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 5th ed. Wayne, PA: National Committee for Clinical Laboratory Standards; 2000. Document M7-A5.
7.National Committee for Clinical Laboratory Standards. Performance Standard for Antimicrobial Susceptibility Testing. Wayne, PA: National Committee for Clinical Laboratory Standards; 2002. Document M100-S12.
8.Diekema, DJ, Pfaller, MA, Jones, RN, et al.Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis 1999;29:595–607.
9.Pfaller, MA, Jones, RN, Biedenbach, DJ, et al.Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC Program (USA). Diagn Microbiol Infect Dis 2001;41:177–182.
10.Karlowsky, JA, Kelly, LJ, Thornsberry, C, et al.Susceptibility to fluoroquinolones among commonly isolated gram-negative bacilli in 2000: TRUST and TSN data for the United States. Int J Antimicrob Agents 2002;19:21–31.
11.Garcia-Rodriguez, J-A, Jones, RN, MYSTIC Programme Study Group. Antimicrobial resistance in gram-negative isolates from European intensive care units: data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme. J Chemother 2002;14:25–32.
12.Ahmad, M, Urban, C, Mariano, N, et al.Clinical characteristics and molecular epidemiology associated with imipenem-resistant Klebsiella pneumoniae. Clin Infect Dis 1999;29:352–355.
13.Itokazu, GS, Quinn, JP, Bell-Dixon, C, et al.Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program. Clin Infect Dis 1996;23:779–784.
14.Fridkin, SK, Hill, HA, Volkova, NV, et al.Temporal changes in prevalence of antimicrobial resistance in 23 U.S. hospitals. Emerg Infect Dis 2002;8:697–701.
15.Goettsch, W, van Pelt, W, Nagelkerke, N, et al.Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in the Netherlands. J Antimicrob Chemother 2000;46:223–228.
16.Livermore, DM, James, D, Reacher, M, et al.Trends in fluoroquinolone (ciprofloxacin) resistance in Enterobacteriaceae from bacteremias, England and Wales, 1990-1999. Emerg Infect Dis 2002;8:473–478.
17.Pfaller, MA, Jones, RN, MYSTIC Study Group (Europe). Antimicrobial susceptibility of inducible AmpC ß-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997-2000. Int J Antimicrob Agents 2002;19:383–388.
18.Fridkin, SK, Steward, CD, Edwards, JR, et al.Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE phase 2. Clin Infect Dis 1999;29:245–252.
19.Chow, JW, Fine, MJ, Shlaes, DM, et al.Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991;115:585–590.
20.Cosgrove, SE, Kaye, KS, Eliopoulous, GM, Carmeli, Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002;162:185–190.